The Medicinal Chemistry Core is a newly proposed CCSG Core. The Medicinal Chemistry Core Laboratory was developed to provide the needed expertise in the area of synthesis of small molecules, modified peptides and bioconjugates for biomedical research by the Cancer Center research community. Creation of this Core was in direct response to a clearly defined need for providing synthesis of chemical reagents needed for preclinical studies (not for clinical drug development). The guiding principle was that the Center was not attempting to establish a GMP chemical production facility, but a chemical synthesis core laboratory to provide reagent grade compounds for use in validation and proof-of-principle target discovery studies. To accomplish this, there are a large number of investigators within the Center who have a need for a Medicinal Chemistry Core to provide unique reagents. These reagents are needed both for the study of the role of specific molecular targets controlling the growth and survival of cancer cells, as well as for the development of related reagents for cancer treatment. From the 2002 inception of the Medicinal Chemistry Core, its mission has been to provide very specific unique reagents to allow proof of principle and general drug discovery studies and accelerate basic sciences studies. The main purpose of the Medicinal Chemistry Core is: (1) To design and synthesize bioactive molecules in the most cost effective manner possible. (2) To optimize methods of purification of bioactive molecules at high yield. (3) To provide NMR, Mass spectrometry, and HPLC analysis for characterization of new anticancer agents. (4) To provide investigators with custom synthesis of anticancer agents in amounts ranging from milligrams to grams. (5) To provide experience and intuition for identification and optimization of lead compounds as well as promising reagents. This application requests support for a resource which continues to fulfill an essential role for peer reviewed research within the SKCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-47
Application #
7821297
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
47
Fiscal Year
2009
Total Cost
$175,241
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hyman, David M; Rizvi, Naiyer; Natale, Ronald et al. (2018) Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res 24:2749-2757
Guo, Hong; Barberi, Theresa; Suresh, Rahul et al. (2018) Progression from the Common Lymphoid Progenitor to B/Myeloid PreproB and ProB Precursors during B Lymphopoiesis Requires C/EBP?. J Immunol 201:1692-1704
Tosoian, Jeffrey J; Guedes, Liana B; Morais, Carlos L et al. (2018) PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer Prostatic Dis :
Tran, Phuong T; Meeker, Alan K; Platz, Elizabeth A (2018) Association between statin drug use and peripheral blood leukocyte telomere length in the National Health and Nutrition Examination Survey 1999-2002: a cross-sectional study. Ann Epidemiol 28:529-534
Pallavajjala, Aparna; Kim, Daehwan; Li, Tongbin et al. (2018) Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. Leuk Lymphoma 59:1231-1238
Dean, Lorraine T; Moss, Shadiya L; Ransome, Yusuf et al. (2018) ""It still affects our economic situation"": long-term economic burden of breast cancer and lymphedema. Support Care Cancer :
Song, Mingyang; Vogelstein, Bert; Giovannucci, Edward L et al. (2018) Cancer prevention: Molecular and epidemiologic consensus. Science 361:1317-1318
Weber, Kari A; Heaphy, Christopher M; Joshu, Corinne E et al. (2018) Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations. Cancer Causes Control 29:759-767
Haffner, Michael C; Taheri, Diana; Luidy-Imada, Eddie et al. (2018) Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proc Natl Acad Sci U S A 115:E8580-E8582
Nauman, Gina; Gray, Javaughn Corey; Parkinson, Rose et al. (2018) Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel) 7:

Showing the most recent 10 out of 2393 publications